title: Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
abstract: The ability of the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model to predict BRCA1 and BRCA2 mutations and breast cancer incidence in women with a family history of breast cancer was evaluated. Observed mutations in 263 screened families were compared to retrospective predictions. Similarly, observed breast cancers in 640 women were compared to retrospective predictions of breast cancer incidence. The ratios of observed to expected number of BRCA1- , BRCA2- and BRCA(1 or 2) mutations were 1.43 (95% CI 1.05-1.90), 0.63 (95% CI 0.34-1.08), and 1.12 (95% CI 0.86-1.44), showing a significant underestimation of BRCA1 mutations. Discrimination between carriers and non-carriers as measured by area under the receiver operating characteristic (ROC) curve was 0.83 (95% CI 0.76-0.88). The ratio of observed to expected number of invasive breast cancers was 1.41 (0.91-2.08). The corresponding area under the ROC curve for prediction of invasive breast cancer at individual level was 0.62 (95% CI 0.52-0.73). In conclusion, the BOADICEA model can predict the total prevalence of BRCA(1 or 2) mutations and the incidence of invasive breast cancers. The mutation probability as generated by BOADICEA can be used clinically as a guideline for screening, and thus decrease the proportion of negative mutation analyses. Likewise, individual breast cancer risks can be used for selecting women whose risk of breast cancer indicates follow-up. Application of local mutation frequencies of BRCA1 and BRCA2 could improve the ability to distinguish between the two genes.
authors: Department of Oncology and Pathology, Karolinska University Hospital, Stockholm, Sweden. anne.kinhult-stahlbom@karolinska.se
authors: Anne Kinhult
authors: AK
authors: Ståhlbom
authors: Hemming
authors: H
authors: Johansson
authors: Annelie
authors: A
authors: Liljegren
authors: Anna
authors: A
authors: von Wachenfeldt
authors: Brita
authors: B
authors: Arver
mesh_terms: D000328:Adult; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000209:etiology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006579:Heterozygote; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D008962:Models, Theoretical; D009154:Mutation / Q000235:genetics*; D059645:Mutation Rate; D011446:Prospective Studies; D012372:ROC Curve; D018570:Risk Assessment
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human